12.49USD-0.24%Mkt Cap: —P/E: —1d ago
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and …
Industry Peers
Healthcare$1.14TUSDP/E 43.0
$658.89BUSDP/E 31.7
$462.68BUSDP/E 74.0
$375.50BUSDP/E 122.7
$341.92BUSDP/E 24.5
$348.81BUSDP/E 25.0
$279.13BUSDP/E 22.3
$274.07BUSDP/E 23.6
$240.45BUSDP/E 24.5
$231.49BUSDP/E 24.5
$238.75BUSDP/E 27.4
$226.85BUSDP/E 33.1
$190.75BUSDP/E 11.3
$198.81BUSDP/E 36.9
$183.02BUSD
$160.96BUSDP/E 37.2
$151.78BUSDP/E 38.6
$142.49BUSDP/E 45.6
$139.84BUSDP/E 32.2
$138.11BUSDP/E 14.9
Key Statistics
Company
Market Cap—
Enterprise Value904.02M $
Revenue (TTM)549.12M $
Gross Profit73.10M $
Net Income (TTM)17.88M $
Revenue/Share3.185 USD
Last Price12.49 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees1.8K
CountryGB
SectorHealthcare
Industry—
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-44.07
EV/Revenue1.65
P/S—
P/B1.73
EPS (TTM)—
EPS (Forward)—
52W Range
12.3032% of range12.91
52W High12.91 USD
52W Low12.30 USD
Profitability
Gross Margin13.31%
Oper. Margin0.31%
EBITDA Margin-3.74%
Profit Margin3.26%
ROE1.46%
ROA-1.24%
Growth
Revenue Growth0.20%
Earnings Growth-96.50%
Cash Flow & Leverage
Operating CF20.46M $
CapEx (TTM)—
FCF Margin-3.44%
FCF Yield—
Net Debt-1.28B $
Net Debt/EBITDA62.49
Balance Sheet
Debt/Equity7.41
Current Ratio5.64
Quick Ratio5.45
Book Value/Sh7.255 USD
Cash/Share7.919 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.—
Float104.59M
Insiders0.01%
Institutions2.70%
Technical
SMA 50—
SMA 200—
Beta0.44
S&P 52W Chg18.16%
Avg Vol (30d)98
Avg Vol (10d)—
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—